Alberta Health Services Adds PERJETA®-HERCEPTIN® Combo Pack for Treatment of
HER2-Positive Metastatic Breast Cancer to the Provincial Formulary
MISSISSAUGA, ON, Jan. 17, 2014 /CNW/ - People with HER2-positive metastatic
breast cancer in Alberta will now be able to access a new treatment option
through the Outpatient Cancer Drug Benefit Program of Alberta Health Services
(AHS). Pertuzumab (PERJETA) and trastuzumab (HERCEPTIN) have been approved
for use in combination with a taxane for the treatment of patients with HER2
positive unresectable locally recurrent or metastatic breast cancer who have
not received prior anti-HER2 therapy or chemotherapy for metastatic disease or
who have not relapsed within six months of receiving trastuzumab in the
"The addition of the PERJETA-HERCPETIN Combo Pack to the Alberta formulary
provides an important option in a HER2-positive metastatic breast cancer
patient's fight against the disease, and we applaud Alberta Health Services
for taking this important step," said Mr. Ronnie Miller, president and CEO,
Roche Canada. "At Roche Canada, we are committed to continually improving
breast cancer treatments through innovative research and development, and we
are pleased that patients in Alberta now have another treatment choice
available to them."
In Canada, breast cancer is the most commonly diagnosed cancer in women.(2)
It accounts for 26 per cent of all cancer cases, making it the second leading
cause of death in women.(2 )On average, 2,100 women in Alberta are diagnosed
with breast cancer every year.(3)
Metastatic (also known as advanced, secondary or stage IV) breast cancer, the
spread of cancer cells from the original site where the cancer first formed to
other parts of the body, is associated with increased severity and is largely
incurable.(4,5 )The median survival for a woman with this form of breast
cancer is two years.(4)
Women with HER2-positive breast cancer test positive for a protein called
human epidermal growth factor receptor (HER2).(6) This protein is found in
high quantities on the outside of HER2-positive breast cancer cells.
HER2-positive breast cancer represents approximately 10 to 20 per cent of
human cancers, and without treatment, it is associated with aggressive tumour
growth and poor clinical outcomes. (5,7,8) Approximately 5,000 women in Canada
are living with this disease.(9)
To-date, British Columbia, Ontario, Saskatchewan and Alberta have funded the
PERJETA-HERCEPTIN Combo Pack.
PERJETA (pertuzumab), in combination with the current standard of care,
HERCEPTIN® (trastuzumab) and docetaxel chemotherapy, is approved by Health
Canada for the treatment of patients with HER2-positive metastatic breast
cancer who have not received prior anti-HER2 therapy or chemotherapy for
The Health Canada approval of PERJETA is largely based on the phase III
CLEOPATRA trial. In the trial, people who received a combination of PERJETA,
HERCEPTIN and docetaxel chemotherapy, lived a median 6.1 months longer without
their cancer getting worse (progression-free survival) compared with the
standard of care, HERCEPTIN plus docetaxel chemotherapy, alone (median PFS
18.5 versus 12.4 months ; HR=0.62; p<0.0001).(9,11 )Further, the combination
of PERJETA, HERCEPTIN and docetaxel chemotherapy significantly extended the
lives of people with previously untreated HER2-positive metastatic breast
cancer (overall survival) compared to HERCEPTIN, docetaxel chemotherapy and
placebo. The risk of death was reduced by 34 per cent for people on the
PERJETA arm of the study, compared to those who received HERCEPTIN and
docetaxel chemotherapy alone (HR=0.66; p=0.0008).(12) At the time of the data
analysis, median overall survival had not yet been reached because more than
half of the patients receiving the PERJETA combination were still alive.(11)
The combination of PERJETA, HERCEPTIN and chemotherapy is thought to provide a
more comprehensive blockade of HER signaling pathways.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Disclaimer: Cautionary statement regarding forward-looking statements
This document may contain certain forward-looking statements. These
forward-looking statements may be identified by words such as 'believes',
'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks',
'estimates', 'future' or similar expressions or by discussion of, among other
things, strategy, goals, plans or intentions. Various factors may cause actual
results to differ materially in the future from those reflected in
forward-looking statements contained in this document, among others: (1)
pricing and product initiatives of competitors; (2) legislative and regulatory
developments and economic conditions; (3) delay or inability in obtaining
regulatory approvals or bringing products to market; (4) fluctuations in
currency exchange rates and general financial market conditions; (5)
uncertainties in the discovery, development or marketing of new products or
new uses of existing products, including without limitation negative results
of clinical trials or research projects, unexpected side effects of pipeline
or marketed products; (6) increased government pricing pressures; (7)
interruptions in production; (8) loss of or inability to obtain adequate
protection for intellectual property rights; (9) litigation; (10) loss of key
executives or other employees; and (11) adverse publicity and news coverage.
The statement regarding earnings per share growth is not a profit forecast and
should not be interpreted to mean that Roche's earnings or earnings per share
for any current or future period will necessarily match or exceed the
historical published earnings or earnings per share of Roche.
(1) Alberta Health Services.
(Accessed January 7, 2014)
(2) Canadian Cancer Society.
n=on (Accessed October 29, 2013)
(3) Canadian Breast Cancer Foundation.
tCancerinCanada.aspx (Accessed January 7, 2014)
(4) Canadian Breast Cancer Network.
March 19, 2013)
(5) BC Cancer Agency.
staticBreastCancer.hm (Accessed March 19, 2013)
(6) Chia et al. Human Epidermal Growth Factor Receptor 2 Overexpression As a
Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast
Cancers, Journal Of Clinical Oncology. 2008;26:5697-5700
(7) Ross et al. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted
Anti-HER-2 Therapy and Personalized Medicine, The Oncologist. 2009;14:320-368
(8) Wolff et al. American Society of Clinical Oncology/College of American
Pathologists Guideline, Recommendations for Human Epidermal Growth Factor
Receptor 2 Testing in Breast Cancer, Arch Patho Lab Med 2007;101:18-43
(9) Tell Her 2 http://tellher2.ca/her2/ (Accessed October 29, 2013)
(10) PERJETA™ Product Monograph. April 12, 2013. Hoffmann-La Roche Limited.
(11) Baselga J, Cortes J, Sung-Bae K, et al. Pertuzumab plus trastuzumab plus
docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366:109-110.
(12) Swain S, et al. Confirmatory overall survival analysis of CLEOPATRA: A
randomized, double-blind, placebo-controlled Phase III study with pertuzumab,
trastuzumab, and docetaxel in patients with HER2-positive first-line
metastatic breast cancer. Poster presented at the 2012 CTRC-AARC San Antonio
Breast Cancer Symposium. Abstract # P5-18-26.
SOURCE Roche Canada
Laura Pagnotta Manager, Corporate Relations Roche Canada 905-542-5853
To view this news release in HTML formatting, please use the following URL:
CO: Roche Canada
NI: MTC NP
-0- Jan/17/2014 15:00 GMT
Press spacebar to pause and continue. Press esc to stop.